検索ワード: immunogeensuse (エストニア語 - 英語)

immunogeensuse andmed
immunogenicity data

täiendavad immunogeensuse andmed
additional immunogenicity data

esineb immunogeensuse võimalus.
there is a potential for immunogenicity with lucentis.

võimalik on immunogeensuse tekkimine.
there is potential for immunogenicity.

täiendavad andmed immunogeensuse kohta
additional immunogenicity data

q4/2016 lõpuks (immunogeensuse aruanne)
by end of q4/2016

hinnati 56 uuringus osaleja immunogeensuse andmeid.
immunogenicity data were evaluated in 64 subjects.

immunogeensuse analüüs tehti immunogeensuse protokollikohastel kohortidel.
the analysis of immunogenicity was conducted on atp cohort for immunogenicity.

immunogeensuse uuringud üle 18-aastastel täiskasvanutel ja eakatel
immunogenicity studies in adults ≥18 years and the elderly

tõhususe puudumist või muid immunogeensuse sümptomeid tuleb uurida.
the loss of efficacy or other symptoms of the development of immunogenicity should be investigated

nagu kõikide valkude puhul, on võimalik immunogeensuse tekkimine.
as with all proteins there is a potential for immunogenicity.

immunogeensuse analüüs tehti immunogeensuse protokollikohastel (atp) kohortidel.
the analysis of immunogenicity was conducted on the atp cohorts for immunogenicity.

immunogeensuse hindamine lastel vanuses 9...12 kuud esimese annuse ajal
evaluation of immunogenicity in children from 9 to 12 months of age at the time of first dose

kartsinogeensusuuringuid ei ole albiglutiidiga läbi viidud närilistel esineva immunogeensuse tõttu.
no carcinogenicity studies have been performed with albiglutide due to immunogenicity in rodents.

immunogeensuse kindlakstehtud või võimalik risk, mis võib viia immuunvahendatud sümptomite tekkeni.
the identified or potential risk of immunogenicity that might lead to immune-mediated symptoms.

immunogeensuse hindamine lastel, kes esimese annuse ajal olid 9...12-kuused
evaluation of immunogenicity in children from 9 to 12 months of age at the time of first dose

vaktsiini ohutuse ja immunogeensuse kohta hiv nakkusega patsientidel on andmeid piiratud hulgal.
in subjects infected with hiv, limited data are available on immunogenicity and safety of the vaccine.

kuna immunogeensuse analüüsid on preparaadispetsiifilised, ei saa võrrelda antikehade teket erinevate ravimite puhul.
because immunogenicity analyses are product-specific, comparison of antibody rates with those from other products is not appropriate.

immunogeensuse analüüs tehti püsivuse atp-kohortidel, mis olid kohandatud iga ajahetke jaoks.
the analysis of immunogenicity was conducted on atp cohort for persistence adapted for each time-point.

immunogeensuse analüüs viidi läbi püsivuse atp-kohortidel, mis olid kohaldatud iga ajahetke jaoks.
the analysis of immunogenicity was conducted on atp cohort for persistence adapted for each time- point. tested at gsk laboratories